Abstract: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder. It is mainly caused by mutations in genes encoding sarcomere proteins. Mutant forms of these highly abundant proteins likely stress the protein quality control (PQC) system of cardiomyocytes. The PQC system, together with a functional microtubule network, maintains proteostasis. We compared left ventricular (LV) tissue of nine donors (controls) with 38 sarcomere mutation-positive (HCM\textsubscript{SMP}) and 14 sarcomere mutation-negative (HCM\textsubscript{SMN}) patients to define HCM and mutation-specific changes in PQC. Mutations in HCM\textsubscript{SMP} result in poison polypeptides or reduced protein levels (haploinsufficiency, HI). The main findings were (1) several key PQC players were more abundant in HCM compared to controls, (2) after correction for sex and age, stabilizing heat shock protein (HSP)B1, and refolding, HSPD1 and HSPA2 were increased in HCM\textsubscript{SMP} compared to controls, (3) α-tubulin and acetylated α-tubulin levels were higher in HCM compared to controls, especially in HCM\textsubscript{HI}, (4) myosin-binding protein-C (cMyBP-C) levels were inversely correlated with α-tubulin, and (5) α-tubulin levels correlated with acetylated α-tubulin and HSPs. Overall, carrying a mutation affects PQC and α-tubulin acetylation. The haploinsufficiency of cMyBP-C may trigger HSPs and α-tubulin acetylation. Our study indicates that proliferation of the microtubular network may represent a novel pathomechanism in cMyBP-C haploinsufficiency-mediated HCM.

Keywords: cardiomyopathy; hypertrophy; sarcomere mutation; haploinsufficiency; poison polypeptide; protein quality control; heat shock proteins; autophagy; microtubules
more complex than the functional defects triggered by the gene mutation. Furthermore, pathogenic mutations were only found in ~50% of all HCM patients [4]. Moreover, a recent large international clinical HCM study showed that patients with a mutation in a sarcomere gene had a 2-fold higher risk of adverse outcomes (e.g., heart failure and atrial fibrillation) compared to patients with no known mutations [5]. The exact mechanisms underlying the difference in disease severity between sarcomere mutation-positive (HCM_{SMP}) and mutation-negative (HCM_{SMN}) patients are currently unknown.

A mechanism implicated in HCM progression is perturbed protein quality control (PQC) [6,7]. Cardiomyocytes contain a multilayered PQC system for maintaining proper protein conformation and for reorganizing and removing misfolded or aggregated (mutant) proteins [8]. The PQC system comprises heat shock proteins (HSPs), the ubiquitin-proteasome system (UPS), and autophagy [9]. HSPs are involved at all stages of sustaining protein homeostasis: during protein biosynthesis and maturation, in chaperoning the folding, in protection from environmental stress, in rearrangements of cellular macromolecules during the functional cycles of assembly and disassembly, and finally, in targeting proteins for degradation [10]. Terminally misfolded and aggregation-prone proteins are cleared by the two degradation systems, UPS and autophagy [11]. Furthermore, pathways of PQC are strongly linked to cell architecture, such as the microtubules network [12]. As sarcomere proteins are the most abundant proteins in the heart, maintenance of sarcomere structure and functions depends on functioning PQC mechanisms.

Perturbations in PQC mechanisms may be aggravated by the presence of sarcomere gene mutations that may explain the difference in disease severity between HCM_{SMP} and HCM_{SMN} patient groups. Moreover, the proteotoxic burden on PQC may depend on the type of mutation: in HCM, gene mutations either result in a ‘poison polypeptide’ (an expressed protein containing a mutated sequence) or haploinsufficiency, where up-regulation of the wild-type protein levels failed to compensate for reduced total protein [13,14].

Here, we identified and quantified key PQC players, such as HSPs and degradation markers (ubiquitinated proteins, p62, LC3BII) and microtubule network markers (for example acetylation of α-tubulin) in a large set of myectomy samples from HCM_{SMP} and HCM_{SMN} patients to define if the presence of a sarcomere mutation differentially affects PQC. In addition, mutation-specific PQC changes were assessed by comparing HCM with missense mutations and MYBPC3 (cardiac myosin-binding protein-C) mutations, which cause haploinsufficiency.

2. Materials and Methods

2.1. Septal Myectomy

Cardiac tissue from the interventricular septum was obtained during myectomy surgery to relieve left ventricular (LV) outflow tract obstruction. Patients were selected for surgery at our HCM center on the basis of the following indications: (1) peak left ventricular outflow tract (LVOT) gradient ≥ 50 mmHg at rest or on provocation and (2) presence of unacceptable symptoms, despite maximally tolerated medications consisting of β-blocking agents and/or calcium channel blockers. The decision to perform surgery was made after the consensus of a heart team consisting of a cardiothoracic surgeon, an interventional cardiologist, and a cardiologist specialized in HCM care [15]. Hypertrophic obstructive cardiomyopathy was evident from the increased septal thickness with a mean (± SD) of 21 (± 6) mm and high LV outflow tract pressure gradient with a mean (± SD) of 66 (± 37) mmHg. Next-generation-sequencing was used to check 48 different HCM-associated genes for variants [16].

This study included 52 septal myectomy patients, as summarized in Table 1. A total of 38 HCM patients were tested positive for carrying a gene variant in one of the genes encoding for the sarcomeric protein. The ages of all 38 HCM_{SMP} patients ranged between 15 and 72, with a mean (± SD) of 49 (± 16) years, and 68% of these were males. Depending on the reported pathomechanism, this group was subdivided into haploinsufficiency (HI) and poison polypeptide (PP) subgroups.
Table 1. Characteristics of controls and manifest HCM patients.

| Number | Code | Pathomechanism | Affected Gene | Gene/Protein Variant | Type of Mutation | Sex (F/M) | Age | ST (mm) | LVOT (mmHg) |
|--------|------|----------------|---------------|----------------------|------------------|-----------|-----|--------|-------------|
| 1      | HCM 42 [17–20] | HI | MYBPC3 | c.2373dupG | truncation | M | 32 | 23 | 64 |
| 2      | HCM 43 [18–22] | HI | MYBPC3 | c.2373dupG | truncation | M | 60 | 23 | 77 |
| 3      | HCM 103 [20] | HI | MYBPC3 | c.2373dupG | truncation | M | 26 | 20 | 13 |
| 4      | HCM 104 [20] | HI | MYBPC3 | c.2373dupG | truncation | M | 33 | 24 | 31 |
| 5      | HCM 120 [20] | HI | MYBPC3 | c.2373dupG | truncation | M | 27 | 24 | 61 |
| 6      | HCM 123 [20] | HI | MYBPC3 | c.2373dupG | truncation | F | 59 | 12 | 64 |
| 7      | HCM 169 [20] | HI | MYBPC3 | c.2373dupG | truncation | M | 52 | - | - |
| 8      | HCM 34 [18,20,23] | HI | MYBPC3 | c.1790G > A; p.Arg597Gln | missense | F | 47 | 20 | 38 |
| 9      | HCM 36 [17,18,20–25] | HI | MYBPC3 | c.927-2A > G | truncation | M | 22 | 30 | 71 |
| 10     | HCM 47 [19,20,23,25] | HI | MYBPC3 | c.3407_3409delACT | truncation | M | 55 | 25 | 96 |
| 11     | HCM 52 [18–20] | HI | MYBPC3 | c.2827C > T | truncation | F | 24 | 24 | 34 |
| 12     | HCM 62 [17,18,20,23] | HI | MYBPC3 | c.772G > A; p.Glu258Lys | missense | M | 35 | 27 | 3 |
| 13     | HCM 63 [20,23] | HI | MYBPC3 | c.2827C > T | truncation | M | 33 | 21 | 25 |
| 14     | HCM 71 [20] | HI | MYBPC3 | c.2827C > T | truncation | M | 49 | 16 | 9 |
| 15     | HCM 82 [20] | HI | MYBPC3 | c.2783C > T; p.Ser928Leu | missense | M | 71 | 20 | 64 |
| 16     | HCM 113 [17,20] | HI | MYBPC3 | c.2827C > T | truncation | M | 21 | 45 | 27 |
| 17     | HCM 116 [20] | HI | MYBPC3 | c.2827C > T | truncation | F | 53 | - | - |
| 18     | HCM 124 [20] | HI | MYBPC3 | c.2827C > T | truncation | M | 53 | 21 | 41 |
| 19     | HCM 133 [20] | HI | MYBPC3 | c.442G > A | truncation | M | 58 | - | - |
| 1      | HCM 27 [18–20,25] | PP | MYH7 | c.4130C > T; p.Thr1377Met | missense | F | 58 | 20 | 100 |
| 2      | HCM 42B [18–20,23,25] | PP | MYH7 | c.1816G > A; p.Val606Met | missense | F | 46 | 20 | 77 |
| 3      | HCM 80 [20] | PP | MYH7 | c.1291G > C and c.4327G > A; p.Val431Leu and p.Asp1443Asn | missense | M | 34 | 17 | 85 |
| 4      | HCM 92 [20] | PP | MYH7 | c.2685A > C; p.Gln895His | missense | M | 66 | - | - |
| 5      | HCM 106 [20] | PP | MYH7 | c.2783A > T; p.Asp928Val | missense | M | 35 | 16 | 16 |
| 6      | HCM 114 [20] | PP | MYH7 | c.976G > C; p.Ala326Pro | missense | M | 69 | 19 | 71 |
| Number | Code    | Reported Pathomechanism | Affected Gene | Gene/Protein Variant | Type of Mutation | Sex (F/M) | Age | ST (mm) | LVOT (mmHg) |
|--------|---------|-------------------------|---------------|----------------------|------------------|-----------|-----|---------|--------------|
| 7      | HCM 119 [20] | PP                      | MYH7          | c.3367G > A; p.Glu1123Gln | missense        | M         | 41  | 20      | 81           |
| 8      | HCM 130 [20] | PP                      | MYH7          | c.976G > C; p.Ala326Pro | missense        | M         | 72  | 18      | 27           |
| 9      | HCM 131  | PP                      | MYH7          | c.1987C > T; p.Arg663Cys | missense        | F         | 52  | 21      | 41           |
| 10     | HCM 166 [20] | PP                      | MYH7          | c.2080C > T; p.Arg694Cys | missense        | F         | 66  |         |              |
| 11     | HCM 55 [18,23,25] | PP                      | TNNI3         | c.433C > T; p.Arg145Trp | missense        | M         | 46  | 23      | 100          |
| 12     | HCM 59 [18,25] | PP                      | TNNI3         | c.433C > T; p.Arg145Trp | missense        | M         | 66  | 16      | 67           |
| 13     | HCM 163  | PP                      | TNNI3         | c.433C > T; p.Arg145Trp | missense        | F         | 64  |         |              |
| 14     | HCM 170  | PP                      | TNNI3         | c.433C > T; p.Arg145Trp | missense        | F         | 69  |         |              |
| 15     | HCM 132  | PP                      | TNNT2         | c.814C > T; p.Arg272Cys | missense        | F         | 15  |         |              |
| 16     | HCM 173  | PP                      | TNNT2         | c.832C > T; p.Arg278Cys | missense        | M         | 58  |         |              |
| 17     | HCM 175  | PP                      | TNNT2         | c.832C > T; p.Arg278Cys | missense        | M         | 61  |         |              |
| 18     | HCM 135  | PP                      | MYL2          | c.64G > A; p.Glu222Lys  | missense        | M         | 68  |         |              |
| 19     | HCM 88   | PP                      | MYL2          | c.401A > C; p.Glu134Ala | missense        | F         | 57  |         |              |

1 | HCM 30 [18,19,26] | SMN | - | F | 72 | 24 | 88 |
2 | HCM 40   | SMN | - | M | 22 | 15 | 100 |
3 | HCM 90   | SMN | - | M | 53 | 17 | 61 |
4 | HCM 96   | SMN | - | M | 74 | 17 | 81 |
5 | HCM 100  | SMN | - | F | 41 | -  | 81 |
6 | HCM 105  | SMN | - | M | 65 | 16 | 49 |
Table 1. Cont.

| Number | Code       | Reported Pathomechanism | Affected Gene | Gene/Protein Variant | Type of Mutation | Sex (F/M) | Age | ST (mm) | LVOT (mmHg) |
|--------|------------|-------------------------|---------------|----------------------|------------------|-----------|-----|---------|-------------|
| 7      | HCM 109    | SMN                     |               |                      | -                | F         | 71  | 20      | 130         |
| 8      | HCM 117 [17] | SMN                  |               |                      | -                | F         | 50  | 16      | 159         |
| 9      | HCM 125 [17] | SMN                  |               |                      | -                | M         | 66  | 18      | 132         |
| 10     | HCM 126    | SMN                     |               |                      | -                | F         | 64  | 15      | 104         |
| 11     | HCM 156    | SMN                     |               |                      | -                | F         | 54  | -       | -           |
| 12     | HCM 168    | SMN                     |               |                      | -                | M         | 46  | -       | -           |
| 13     | HCM 172    | SMN                     |               |                      | -                | M         | 57  | -       | -           |
| 14     | HCM 174    | SMN                     |               |                      | -                | M         | 66  | -       | -           |
| 1      | 3145 [27–39] | Ctrl                  |               |                      | -                | M         | 39  | -       | -           |
| 2      | 4021 [33–45] | Ctrl                  |               |                      | -                | F         | 53  | -       | -           |
| 3      | 4049 [33–42,46–51] | Ctrl               |               |                      | -                | M         | 65  | -       | -           |
| 4      | 5126 [46–49,52] | Ctrl               |               |                      | -                | F         | 55  | -       | -           |
| 5      | 6008 [42,53–55] | Ctrl               |               |                      | -                | M         | 40  | -       | -           |
| 6      | 7012 [27–32,56,57] | Ctrl             |               |                      | -                | M         | 19  | -       | -           |
| 7      | 7040 [33–36,55,58] | Ctrl             |               |                      | -                | M         | 37  | -       | -           |
| 8      | 7054 [55,59] | Ctrl                  |               |                      | -                | M         | 33  | -       | -           |
| 9      | 8004 [55]   | Ctrl                  |               |                      | -                | F         | 50  | -       | -           |

HI: haploinsufficiency; PP: poison polypeptide; SMN: sarcomere mutation-negative; Ctrl: healthy donor hearts; F: female; M: male; Age: age at time of surgery; ST: septal thickness; LVOT: left outflow tract pressure gradient at rest. Patients without significant obstruction (LVOT gradient < 20 mmHg), but with severe heart failure symptoms, received an extended myectomy in order to increase LV filling.
Seven patients of the HCM$_{HI}$ group were identified as carrying the Dutch founder mutation (c.2373dupG) in MYBPC3, the gene encoding the A band protein, cardiac myosin-binding protein-C (cMyBP-C) and twelve patients carried other mutations in MYBPC3, of which three were missense and the remainder were truncations. Patient ages ranged between 21 and 71 years, with a mean (± SD) of 43 (± 15) years, and 79% of these were males. We collected 19 myectomy samples from HCM$_{PP}$ patients carrying a missense mutation. Nine patients presented with mutations in the gene for the cardiac myosin heavy chain (MYH7), the second most commonly mutated gene in HCM patients. Four patients carried mutations in the gene for troponin I (TNNT1), three patients carried troponin T (TNNT2) mutations and two patients carried myosin light chain 2 (MYL2) mutations. The HCM$_{PP}$ patients were aged between 15 and 72 years, with a mean (± SD) of 55 (± 15) years, and 58% of these were males.

Our study included 14 patients with no known sarcomere gene mutation. HCM$_{SMN}$ patient ages ranged between 22 to 74, with a mean (± SD) of age 57 (± 14), and 64% of these were males. Not all the myectomy samples were sufficiently large to perform all the analyses.

Finally, the 52 HCM samples were compared with nine samples of healthy donor hearts that were not used for heart transplantation, mostly because of poor tissue matching against patients in the heart failure clinic of St Vincent’s Hospital. While these controls had no history of cardiac disease, their validity as “controls” was based on their extensive use as such in publications from a wide range of other laboratories. We therefore assumed that these donors are representative of the diverse human population. Consistent with the HCM patients, these donors were 67% male, with a mean age (± SD) of 43 (± 14) years, ranging from 19 to 65. All donor hearts were perfused with ice-cold cardioplegia and transported on ice to the Sydney Heart Bank where ~1 g samples were snap frozen and stored in liquid nitrogen. The average values of the control cardiac samples ($n = 9$) are indicated by the dotted lines in Figures 1 to 4 and Figure 6. The distribution of the controls is shown in the Supplementary Materials (Figure S1), as well as uncropped full-width images of the membranes (Figure S2). The patients study protocol was approved by the local ethics committees and the donor hearts were approved by the University of Sydney (HREC #7326). All the collections were made with written informed consent obtained from each patient prior to surgery and from the donors’ next of kin.

2.2. Whole Protein Isolation

Frozen tissue was dissected on dry ice and homogenized with RIPA buffer (0.05 M C$_4$H$_{11}$NO$_3$·HCl pH 8.0, 0.15 M NaCl, 1% IGEPAL CA-630, 0.5% sodium deoxycholate, 1% sodium dodecyl sulfate) using a Tissuelyser II (Qiagen). The lysates were centrifuged and the supernatant was collected and passed through an insulin syringe (Becton Dickinson Microlance needle, 25 gauge). Whole protein lysate was mixed with the 4× Laemmli sample buffer (8% sodium dodecyl sulfate, 40% glycerol, 0.04% bromophenol blue, 0.240 M C$_4$H$_{11}$NO$_3$·HCl pH 6.8, 10 mM β-mercaptoethanol, 0.01 M NaF, 0.001 M Na$_3$VO$_4$, Complete mini protease inhibitor cocktail (Roche)), boiled for 5 min and stored at −80 °C.

2.3. Electrophoresis and Western Blots

Equal amounts of protein (10 µg) were separated on pre-cast SDS-PAGE 4–12% criterion gels (Bio-Rad) and transferred onto nitrocellulose membranes (Bio-Rad). The membranes were blocked in 5% skim milk/1× TBST for 1 h at room temperature and incubated overnight at 4 °C with the following primary antibodies in 3% BSA/1× TBST: mouse anti-acetylated α-tubulin (T7451, Sigma-Aldrich, Saint Louis, MO, USA), mouse anti-α-actinin (A7811, Merck KGaA, Darmstadt, Germany), mouse anti-HSPA1 (ADI-SPA-810, Enzo Life Sciences, Zandhoven, Belgium), mouse anti-HSPA2 (66291-1, Proteintech Group, Rosemont, IL, USA), mouse anti-HSPB1 (ADI-SPA-800, Enzo Life Sciences, Zandhoven, Belgium), rabbit anti-HSPB5 (ADI-SPA-223, Enzo Life Sciences, Zandhoven, Belgium), rabbit anti-HSPB7 (ab150390, Abcam, Cambridge, UK), rabbit anti-HSPD1 (ADI-SPA-805, Enzo Life Sciences, Zandhoven, Belgium), mouse anti-GAPDH (10R-G109a, Fitzgerald Industries International, Acton, MA, USA), mouse anti-LC3B (#2775, Cell Signaling Technology, Danvers, MA, USA), rabbit anti-p62 (#5114, Cell Signaling Technology), mouse anti-α-tubulin (T9026, Sigma-Aldrich), and
rabbit anti-ubiquitin (#3933, Cell Signaling Technology). The membranes were incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibody (DakoCytomation, Santa Clara, CA, USA), raised in goat, in 3% BSA/1x TBST. Signals were detected by Amersham Imager 600 (GE Healthcare, Chicago, IL, USA) and quantified by densitometry (ImageQuant TL, GE Healthcare). To correct for loading differences, protein amounts were expressed relative to GAPDH.

2.4. Statistical Analyses

Data were analyzed with SPSS Statistics version 22.0 for Windows (IBM Corporation, Armonk, NY, USA) and GraphPad Prism version 7.0 (GraphPad Software Inc., San Diego, CA, USA). Data in figures are presented as means ± standard errors of the mean (SEM) per group and in the text, data are presented as means ± standard deviations (SD). The distribution of each data set was determined by Q-Q plots and then double checked by Kolmogorov-Smirnov and Shapiro Wilk tests after data collection was completed. Normally distributed data were analyzed with unpaired t-test (comparing 2 groups) and ordinary one-way ANOVA (comparing > 2 groups) with Tukey’s multiple comparisons post-hoc test (comparing ≤ 3 groups) and Dunnett’s multiple comparisons post-hoc test (comparing > 3 groups). To analyze non-parametric data, the Mann-Whitney U test (comparing 2 groups) and the Kruskal-Wallis test with Dunn’s multiple comparisons post-hoc test (comparing > 2 groups) were used. A two-sided p < 0.05 was considered to indicate statistical significance. Multivariate generalized linear model testing (detailed description in the Supplementary Materials) was performed to study the main effects of different mutation groupings, sex, and age at operation on PQC proteins, which were used as dependent variables.

3. Results

3.1. Changes of Protein Quality Control in HCM_{SMP} and HCM_{SMN}

We investigated the expression levels of key PQC proteins to determine if they were altered in patients with HCM at the time of myectomy compared with the levels in LV samples from healthy controls. As the mutant sarcomere proteins may directly affect PQC, we used Western blots to compare myectomy samples from 38 HCM_{SMP} and 14 HCM_{SMN} patients with LV tissue from nine healthy controls that were age- and sex-matched to the HCM samples (Table 1).

3.1.1. HSPs that Stabilize Target Proteins

Dependent on their function, HSPs were classified in two categories: stabilizing HSPs and HSPs with refolding capacity. Stabilizing HSPs (HSPB1 (also known as HSP27), HSPB5 (αB-crystallin), HSPB7 (cardiovascular HSP)) have relatively low molecular weights (15–30 kDa). They stabilize misfolded proteins using an ATP-independent holdase activity, thereby preventing their aggregation (Figure 1A). Compared to controls, the HCM_{SMP} samples expressed significantly higher levels of HSPB1 and HSPB7, while HSPB5 appeared to be unaltered (Figure 1C; Table 2).

We then quantified the protein levels of these stabilizing HSPs (HSPB1, HSPB5 and HSPB7) in HCM_{SMN} samples. Only HSPB7 was significantly higher in HCM_{SMN} compared to controls (Figure 1C; Table 2). Despite this, there were no significant differences in stabilizing HSP's levels between HCM_{SMP} and HCM_{SMN}.
Table 2. Overview of results on statistical testing for differences between controls, HCM\textsubscript{SMP} and HCM\textsubscript{SMN}.

| Proteins     | Statistical Test     | p Value | Controls vs. HCM\textsubscript{SMP} | Controls vs. HCM\textsubscript{SMN} | HCM\textsubscript{SMP} vs. HCM\textsubscript{SMN} |
|--------------|----------------------|---------|-------------------------------------|-------------------------------------|-----------------------------------------------|
| **Stabilizing HSPs** |                      |         |                                     |                                     |                                               |
| HSPB1        | Kruskal-Wallis       | 0.0019  | 0.0018                             | 0.2113                             | 0.3302                                        |
| HSPB5        | Ordinary one-way ANOVA | 0.1297  | 0.1090                             | 0.3807                             | 0.8174                                        |
| HSPB7        | Kruskal-Wallis       | 0.0060  | 0.0048                             | 0.0341                             | >0.9999                                       |
| **Refolding HSPs** |                      |         |                                     |                                     |                                               |
| HSPD1        | Ordinary one-way ANOVA | 0.0004  | 0.0003                             | 0.0530                             | 0.2123                                        |
| HSPA1        | Kruskal-Wallis       | 0.3636  | 0.6382                             | >0.9999                            | >0.9999                                       |
| HSPA2        | Ordinary one-way ANOVA | 0.0101  | 0.0071                             | 0.1008                             | 0.7334                                        |
| **Protein degradation** |                   |         |                                     |                                     |                                               |
| Ubiquitin    | Kruskal-Wallis       | 0.2159  | 0.3094                             | >0.9999                            | 0.9890                                        |
| p62          | Ordinary one-way ANOVA | 0.1087  | 0.5822                             | 0.7531                             | 0.1046                                        |
| LC3BII       | Kruskal-Wallis       | 0.0451  | 0.0384                             | 0.2455                             | >0.9999                                       |
| **Tubulin network** |                    |         |                                     |                                     |                                               |
| α-tubulin    | Ordinary one-way ANOVA | <0.0001 | <0.0001                           | 0.0119                             | 0.0019                                        |
| Acetylated α-tubulin | Kruskal-Wallis   | <0.0001 | <0.0001                           | 0.0451                             | 0.0516                                        |

p < 0.05 is considered to be significant.
Cells 2019, 8, x FOR PEER REVIEW 8 of 27

Figure 1. Stabilizing HSPs. (a) Under stress conditions when native proteins are destabilized and begin to unfold, stabilizing HSPs dissociate from homo- and/or heterogeneous oligomeric complexes into dimers to bind these partially misfolded proteins. Thereby, stabilizing HSPs prevent the aggregation of misfolded proteins. Figure reproduced and adapted with permission from Dorsch, L.M. et al., Pflügers Archiv–European Journal of Physiology; published by Springer Berlin Heidelberg, 2018. (b) Representative blot images for HSPB1, HSPB5, and HSPB7 expression. (c) Higher levels of HSPB1 and HSPB7 in HCM~SMP~ ($n = 38$) compared to controls. Higher HSPB7 levels in HCM~SMN~ ($n = 12$) compared to controls ($n = 9$; average is shown as dotted line). HSPB1 and HSPB5 protein levels were not different in HCM~SMP~ ($n = 14$) compared to controls. There were no significant differences between HCM~SMP~ and HCM~SMN~. Each dot in the scatter plots represents an individual sample. * $p < 0.05$ and ** $p < 0.01$ versus controls.

3.1.2. HSPs That Refold Target Proteins

Next we investigated the expression levels of HSPD1 (HSP60), HSPA1 (HSP70 and HSP72) and HSPA2 (HSP70-2) that have an ATP-dependent folding activity. These HSPs have molecular weights >30 kDa and either refold misfolded proteins or assist in their degradation. HSPD1 is mainly located in mitochondria while HSPA1 and HSPA2 are cytosolic, but when they are exposed to heat stress,
both translocate to the nucleus [60,61]. Compared to controls, significantly higher levels of HSPD1 and HSPA2 were observed in HCM_{SMP} samples, while HSPA1 levels were not significantly changed. Levels of HSPs with a refolding capacity were not significantly different in HCM_{SMN} compared to controls, although HSPD1 and HSPA2 showed a trend to higher levels. There were no significant differences in HSPs with a refolding capacity between the two HCM groups (Figure 2; Table 2).

Figure 2. HSPs with a refolding capacity. (a) HSPs with ATPase activity and stabilizing HSPs bind to the misfolded protein to stabilize and further process it. HSPs with a refolding capacity either refold the misfolded protein to its native structure or, if refolding is impossible, the HSPs assist in the degradation pathways to degrade the misfolded protein. Figure reproduced and adapted with permission from Dorsch, L.M. et al., Pflügers Archiv—European Journal of Physiology, published by Springer Berlin Heidelberg, 2018. (b) Representative blot images for HSPD1, HSPA1, and HSPA2 expression. (c) Higher levels of HSPD1 and HSPA2 in HCM_{SMP} ($n = 38$) compared to controls. HSPs with refolding capacity were unaltered in HCM_{SMN} (HSPD1, HSPA1: $n = 14$; HSPA2: $n = 12$) compared to controls. There were no significant differences between HCM_{SMP} and HCM_{SMN}. Each dot in the scatter plots represents an individual sample. ** $p < 0.01$ and *** $p < 0.001$ versus controls.
3.1.3. Degradation of Proteins

PQC is also involved in the degradation of proteins and therefore levels of ubiquitination, p62 and LC3BII were assessed. The antibody used for ubiquitin recognizes polyubiquitinated proteins without distinguishing between K48-linked polyubiquitin chains (predominantly targeted by proteasomal degradation) and K63-linked polyubiquitin chains (targeted by autophagic degradation) [62]. Levels of ubiquitin and the ubiquitin-binding autophagic adaptor protein p62 were unaltered in both HCM groups compared to controls. Levels of the autophagosome marker LC3BII were significantly higher in HCM SMP compared to controls, while only some samples of the HCM SMN group had higher levels of LC3BII (Figure 3, Table 2).

![Degradation pathways](image)

**Figure 3.** Degradation pathways. (a) Misfolded proteins with polyubiquitin chains linked via lysine 48 (K48) are mainly degraded by the proteasome. Misfolded proteins carrying K63-linked polyubiquitin chains and aggregated proteins enter the autophagic pathway. Figure reproduced and adapted with permission from Dorsch, L.M. et al., Pflügers Archiv—European Journal of Physiology; published by Springer Berlin Heidelberg, 2018. (b) Representative blot images for ubiquitin, p62, and LC3BII expression. (c) Protein levels of ubiquitin and p62 did not differ between HCM and controls samples. Higher levels of LC3BII in HCM SMP (n = 38) compared to controls. There were no significant differences between HCM SMP and HCM SMN (ubiquitin, p62: n = 12; LC3BII: n = 13). Each dot in the scatter plots represents an individual sample. *p < 0.05 versus controls.

To ensure that the significant differences detected by ANOVA testing were not related to differences in age and/or sex of the myectomy patients, we performed multivariate testing (Wilks’ Lambda test). This test uses age, sex and the HCM grouping (controls, HCM SMP and HCM SMN) as the effects and the HSPs, ubiquitination, p62, and LC3BII as dependent variables. We found an overall significant difference in the levels of key PQC players based on the different mutation groups (Table 3), while sex and age at operation had no significant effect on levels of key PQC players. To determine which of the individual key PQC players differed among groups when taking into account sex and age, we...
performed tests for between-subjects effects. This test revealed statistically significant differences among groups for HSPB1 and HSPD1 (Table 4).

**Table 3. Multivariate Tests**<sup>a</sup>: HCM grouping (controls, HCM<sub>SMP</sub>, and HCM<sub>SMN</sub>), sex and age at operation.

| Effect         | Value  | F      | Hypothesis df | Error df | Significance | Partial eta Squared |
|----------------|--------|--------|---------------|----------|--------------|---------------------|
| Intercept      | 0.260  | 14.561 | 9.000         | 46.000   | <0.001       | 0.740               |
| HCM grouping   | 0.479  | 2.278  | 18.000        | 92.000   | 0.006        | 0.308               |
| Sex            | 0.754  | 1.664  | 9.000         | 46.000   | 0.126        | 0.246               |
| Age at operation | 0.717 | 2.016  | 9.000         | 46.000   | 0.059        | 0.283               |

<sup>a</sup> Design: Intercept and HCM grouping and sex and age at operation; <sup>b</sup> exact statistic; F: F statistic for the given effect and test statistic; Hypothesis df: Number of degrees of freedom in the model; Error df: Number of degrees of freedom associated with the model errors; Partial eta squared: estimate of effect size; <i>p</i> < 0.05 is considered to be significant.

**Table 4. Tests for between-subjects: HCM grouping (controls, HCM<sub>SMP</sub>, HCM<sub>SMN</sub>) as an effect and correction for differences in sex and age at operation.**

| Type of Stabilizing or Degradation | HSPs | Type III Sum of Squares | df | Mean Square | F      | Significance | Partial eta Squared | R squared |
|----------------------------------|------|-------------------------|----|-------------|--------|--------------|---------------------|-----------|
| Stabilizing HSPs                 |      |                         |    |             |        |              |                     |           |
| HSPB1                            |      | 23.286                  | 2  | 11.643      | 6.0313 | <0.004       | 0.182               | 0.261     |
| HSPB5                            |      | 1.777                   | 2  | 0.889       | 2.495  | 0.092        | 0.085               | 0.088     |
| HSPB7                            |      | 9.725                   | 2  | 4.863       | 3.319  | 0.044        | 0.109               | 0.162     |
| Refolding HSPs                   |      |                         |    |             |        |              |                     |           |
| HSPD1                            |      | 11.104                  | 2  | 5.552       | 10.543 | <0.001       | 0.281               | 0.323     |
| HSPA1                            |      | 0.258                   | 2  | 0.129       | 0.981  | 0.381        | 0.035               | 0.055     |
| HSPA2                            |      | 1.724                   | 2  | 0.862       | 5.114  | 0.009        | 0.159               | 0.171     |
| Protein degradation              |      |                         |    |             |        |              |                     |           |
| Ubiquitin                        |      | 1.433                   | 2  | 0.716       | 2.101  | 0.132        | 0.072               | 0.097     |
| p62                              |      | 0.733                   | 2  | 0.367       | 2.498  | 0.092        | 0.085               | 0.122     |
| LC3BII                           |      | 12.839                  | 2  | 6.420       | 2.276  | 0.112        | 0.078               | 0.111     |

<sup>df</sup>: Number of degrees of freedom in the model; <sup>F</sup>: F statistic for the given effect and test statistic; Partial eta squared: estimate of effect size; <i>R</i> squared: proportion of the variance in the dependent variable that is predictable from the independent variable; Bonferroni correction: statistical significance at <i>p</i> < 0.0056 (<i>α</i>/9 = 0.05/9 = 0.0056).

Since we found between-subjects main effects, we performed a contrast analysis to determine significant pairwise differences between controls and the two HCM patient groups corrected for age and sex. A simple main effects analysis revealed significantly higher levels of HSPB1, HSPD1 and HSPA2 in HCM<sub>SMP</sub> compared to controls (Table 5), while a trend to higher levels of HSPD1 was observed in HCM<sub>SMN</sub>.

Overall, our analyses showed increased levels of several HSPs in HCM<sub>SMP</sub> and HCM<sub>SMN</sub> compared to controls, while no significant differences between HCM<sub>SMP</sub> and HCM<sub>SMN</sub> were observed.
Table 5. Simple Contrast Results (K Matrix) for HCM grouping (controls, HCM_{SMP}, HCM_{SMN}) as an effect and correction for differences in age at operation and sex.

|                      | Stabilizing HSPs | Refolding HSPs | Protein Degradation |
|----------------------|------------------|----------------|---------------------|
|                      | HSPB1 | HSPB5 | HSPB7 | HSPD1 | HSPA1 | HSPA2 | Ubiquitin | p62 | LC3BII |
| HCM_{SMP} vs. controls |      |       |       |       |       |       |           |     |        |
| Contrast Estimate     | 1.804 | 0.447 | 1.164 | 1.242 | 0.177 | 0.491 | 0.441      | 0.128 | 1.319 |
| Standard error        | 0.520 | 0.223 | 0.453 | 0.271 | 0.136 | 0.154 | 0.218      | 0.143 | 0.628 |
| Significance          | 0.001 | 0.050 | <0.001| 0.198 | 0.002 | 0.049 | 0.375      |      | 0.040 |
| 95% Confidence Interval for |     |       |       |       |       |       |           |     |        |
| Lower Bound           | 0.761 | −0.0002 | 0.257 | 0.698 | −0.095 | 0.183 | 0.003      | −0.159 | 0.060 |
| Upper Bound           | 2.848 | 0.895 | 2.072 | 1.786 | 0.449 | 0.799 | 0.878      | 0.415 | 2.578 |
| HCM_{SMN} vs. controls |      |       |       |       |       |       |           |     |        |
| Contrast Estimate     | 1.522 | 0.178 | 0.929 | 0.961 | 0.086 | 0.452 | 0.301      | −0.160 | 1.335 |
| Standard error        | 0.650 | 0.279 | 0.565 | 0.339 | 0.169 | 0.192 | 0.273      | 0.179 | 0.784 |
| Significance          | 0.023 | 0.524 | 0.106 | 0.006 | 0.613 | 0.031 | 0.274      | 0.374 | 0.094 |
| 95% Confidence Interval for |     |       |       |       |       |       |           |     |        |
| Lower Bound           | 0.220 | −0.380 | −0.204 | 0.282 | −0.253 | 0.041 | −0.245      | −0.519 | −0.236 |
| Upper Bound           | 2.825 | 0.737 | 2.062 | 1.641 | 0.426 | 0.810 | 0.848      | 0.198 | 2.907 |

Bonferroni correction: statistical significance at \( p < 0.0028 \) (\( \alpha/18 = 0.05/18 = 0.0028 \)).
3.2. Changes of Protein Quality Control: HCM Disease Mechanism

All the studied HCM\textsubscript{SMP} patients were heterozygous for the mutation, implying the potential to produce either or both the mutant and wild-type protein [14]. Either the expression of the mutant protein, which above a threshold (the ‘poison polypeptide’ mechanism) level might become toxic or have an inability to upregulate the haplotype protein levels to meet the needs of the heart (the ‘haploinsufficiency’ mechanism) might underlie HCM [14]. Truncation and missense MYBPC3 mutations usually involve haploinsufficiency as the disease mechanism since total cMyBP-C protein level is lower and the mutant protein has not been detected in human myectomy samples [13,63]. We determined whether key PQC players were differently changed in samples with haploinsufficiency (HI) and poison polypeptide (PP) by comparing 19 MYBPC3 mutation samples (HCM\textsubscript{HI}) with 19 HCM\textsubscript{SMP} samples carrying a missense mutation (HCM\textsubscript{PP}). Proteomics analysis using mass spectrometry revealed significantly lower cMyBP-C protein levels in the HCM\textsubscript{HI} samples compared to the HCM\textsubscript{PP} patients, consistent with a protein haploinsufficiency mechanism (Figure 4) [64]. No significant differences in PQC components were observed between HCM\textsubscript{HI} and HCM\textsubscript{PP} (Figure 5, Table 6).

| Proteins          | Statistical Test     | p Value |
|-------------------|----------------------|---------|
| Stabilizing HSPs  |                      |         |
| HSPB1             | Unpaired t-test      | 0.4040  |
| HSPB5             | Unpaired t-test      | 0.6236  |
| HSPB7             | Mann-Whitney U test  | 0.4181  |
| Refolding HSPs    |                      |         |
| HSPD1             | Unpaired t-test      | 0.1712  |
| HSPA1             | Unpaired t-test      | 0.8044  |
| HSPA2             | Unpaired t-test      | 0.2096  |
| Protein degradation|                      |         |
| Ubiquitin         | Unpaired t-test      | 0.6099  |
| p62               | Unpaired t-test      | 0.5868  |
| LC3BII            | Unpaired t-test      | 0.4297  |
| Tubulin network   |                      |         |
| α-tubulin         | Unpaired t-test      | 0.0074  |
| Acetylated α-tubulin| Unpaired t-test    | 0.0079  |
| Acetylated α-tubulin/α-tubulin | Mann-Whitney U test | 0.1629 |

*p < 0.05 is considered to be significant.
Levels of cMyBP-C in HCMHI (n = 19) compared to controls (n = 5) and HCMPP (n = 18). Each dot on the scatter plot represents an individual sample. *** p < 0.001 versus controls and ### p < 0.001 versus HCMPP.

Figure 4. cMyBP-C haploinsufficiency. Mass spectrometry-based proteomics analysis revealed lower levels of cMyBP-C in HCMHI (n = 19) compared to controls (n = 5) and HCMPP (n = 18). Each dot on the scatter plot represents an individual sample. ** ** p < 0.001 versus controls and ### p < 0.001 versus HCMPP.

Figure 5. Pathomechanism of HCM and key PQC players. (a) Stabilizing HSPs (HSPB1, HSPB5, HSPB7), (b) HSPs with refolding capacity (HSPD1, HSPA1, HSPA2) and (c) degradation markers (ubiquitin, p62, LC3BII) were not significantly different between HCMHI (n = 19) and HCMPP (n = 19). Each dot in the scatter plots represents an individual sample. Figure reproduced and adapted with permission from Dorsch, L.M. et al., Pflügers Archiv–European Journal of Physiology; published by Springer Berlin Heidelberg, 2018.

3.3. Microtubule Network

Microtubule-based transport of proteins is required for autophagy and is thus an essential part of PQC. Acetylation of α-tubulin is associated with stable microtubules and is used as a marker of their stability [65,66]. Mouse models of familial HCM showed higher levels of acetylated α-tubulin [67]. Compared to controls, α-tubulin expression levels were significantly higher in both HCMsMP and HCMsMN (Figure 6A,B; Table 2). In addition, acetylation of α-tubulin was significantly higher in both
HCM patient groups compared to controls (Figure 6A,B). The increases in the levels of α-tubulin and acetylated α-tubulin were significantly higher in HCM_{SMP} compared to HCM_{SMN}.

![Image of Figure 6](image_url)

**Figure 6.** Pathomechanism of HCM and acetylation of α-tubulin. (a) Representative blot images for α-tubulin and acetylated α-tubulin. (b) Higher levels of α-tubulin and acetylated α-tubulin in HCM_{SMP} (n = 38) and HCM_{SMN} (α-tubulin: n = 14; acetylated α-tubulin: n = 12) compared to controls. Significant difference of α-tubulin levels between HCM_{SMP} and HCM_{SMN} (##p < 0.01). (c) Higher levels of α-tubulin and acetylated α-tubulin in HCM_{HI} (n = 19) than HCM_{PP} (n = 19). (d) The levels of α-tubulin correlated well with acetylated α-tubulin (e) Significant inverse linear correlation of α-tubulin with cMyBP-C. Controls = open squares, HCM_{SMP} = filled circles, HCM_{SMN} = open circles, HCM_{HI} = filled triangles, HCM_{PP} = filled rhomboids. Each dot in the scatter plots and the correlation analyses represents an individual sample. * p < 0.05 and *** p < 0.001 versus controls and ## p < 0.01 and ### p < 0.001 versus HCM_{PP}.

When comparing mutation types, significantly higher levels of α-tubulin and acetylated α-tubulin were observed in HCM_{HI} compared to HCM_{PP} (Figure 6C, Table 6). The levels of acetylated α-tubulin significantly correlated with α-tubulin (Figure 6D), which is in line with the observation that acetylation of α-tubulin compartmentalized on the stable microtubules. Moreover, a significant inverse linear correlation was present between the cMyBP-C protein level and α-tubulin in HCM with a sarcomere gene mutation (Figure 6E). Overall, these data show that the presence of a sarcomere mutation coincides with a more extensive and stabilized microtubule network in HCM.
3.4. Strong Correlation of HSPs with α-Tubulin

Since the PQC is strongly linked to the microtubules network, we performed multivariate testing (Wilks’ Lambda test) using levels of α-tubulin, sex, and age at operation as effects and the HSPs, ubiquitination, p62, and LC3BII as dependent variables. There was an overall statistically significant difference in the levels of key PQC players based on the α-tubulin levels (Table 7).

Table 7. Multivariate Tests a: α-tubulin (all samples), sex, and age at operation.

| Effect           | Value | F     | Hypothesis df | Error df | Significance | Partial eta Squared |
|------------------|-------|-------|---------------|----------|--------------|---------------------|
| Intercept        | 0.389 | 8.186 | 9.000         | 47.000   | <0.001       | 0.611               |
| α-tubulin        | 0.427 | 7.009 | 9.000         | 47.000   | <0.001       | 0.573               |
| Sex              | 0.774 | 1.523 | 9.000         | 47.000   | 0.168        | 0.226               |
| Age at operation | 0.791 | 1.384 | 9.000         | 47.000   | 0.223        | 0.209               |

* Design: Intercept and α-tubulin and sex and age at operation; b exact statistic; F: F statistic for the given effect and test statistic; Hypothesis df: Number of degrees of freedom in the model; Error df: Number of degrees of freedom associated with the model errors; Partial eta squared: estimate of effect size; p < 0.05 is considered to be significant.

To determine which of the key PQC players differed when α-tubulin levels changed, we performed tests for between-subjects effects. This test revealed that α-tubulin had a significant effect on all the measured HSPs, but not on the degradation markers (Table 8). The correlation of HSPs and α-tubulin levels is visualized in Figure S3.

Table 8. Tests for between-subjects: α-tubulin as an effect and correction for differences in sex and age at operation.

| Stabilizing HSPs | Type III Sum of Squares | df | Mean Square | F     | Significance | Partial eta Squared | R Squared |
|------------------|-------------------------|----|-------------|-------|--------------|---------------------|-----------|
| HSPB1            | 38.460                  | 1  | 38.460      | 23.663| <0.001       | 0.301               | 0.368     |
| HSPB5            | 3.630                   | 1  | 3.630       | 11.485| 0.001        | 0.173               | 0.176     |
| HSPB7            | 14.246                  | 1  | 14.246      | 10.504| 0.002        | 0.160               | 0.209     |

Refolding HSPs

| HSPD1            | 10.273                  | 1  | 10.273      | 19.305| <0.001       | 0.260               | 0.303     |
| HSPA1            | 1.370                   | 1  | 1.370       | 12.580| 0.001        | 0.186               | 0.203     |
| HSPA2            | 1.723                   | 1  | 1.723       | 10.410| 0.002        | 0.159               | 0.171     |

Protein degradation

| Ubiquitin        | 0.419                   | 1  | 0.419       | 1.187 | 0.281        | 0.021               | 0.047     |
| p62              | 0.418                   | 1  | 0.418       | 2.792 | 0.100        | 0.048               | 0.087     |
| LC3BII           | 3.849                   | 1  | 3.849       | 1.312 | 0.257        | 0.023               | 0.058     |

df: Number of degrees of freedom in the model; F: F statistic for the given effect and test statistic; Partial eta squared: estimate of effect size; R squared: proportion of the variance in the dependent variable that is predictable from the independent variable; Bonferroni correction: statistical significance at p < 0.0056 (α/9 = 0.05/9 = 0.0056).

4. Discussion

The incomplete penetrance, age-related onset and the large clinical variability in disease severity imply a complex HCM pathophysiology mechanism. Patients with a sarcomere mutation have a particularly higher risk for adverse outcomes. The underlying causes for the difference in disease between HCM\textsubscript{SMP} and HCM\textsubscript{SMN} remain unclear.

Here, we determined the protein levels of key PQC players, including HSPs and degradation markers, and the acetylation of α-tubulin by Western blot analysis in a large set of cardiac samples from HCM\textsubscript{SMP} and HCM\textsubscript{SMN} patients to define PQC changes in HCM at the time of myectomy, and identified if the presence of a sarcomere mutation mediates changes in PQC mechanisms and tubulin
network. One of the limitations of the current study was that patients had a severe phenotype with LVOT obstruction. Therefore, this group may not be representative for all patients with HCM.

The main findings of our PQC assessment were that: (1) several HSPs and autophagy markers were higher in HCM compared to controls, but there are no major differences between HCM_{SMN} and HCM_{SMN}P or mutation type (haploinsufficiency versus poison polypeptide) at the time of myectomy, (2) after correction for sex and age at operation, the major increases in HCM_{SMN} compared to controls were observed in the stabilizing HSPB1 and the refolding HSPD1 and HSPA2, (3) the most significant increase compared to control samples was observed in the levels of α-tubulin and acetylated α-tubulin, with significant differences between the mutation groups: HCM_{HI} > HCM_{PP} > HCM_{SMN}, and (4) the levels of α-tubulin significantly correlated with the levels of acetylated α-tubulin and all the HSPs (Figure 7).

Overall, our analyses indicate that carrying a HCM-causing mutation affects PQC and α-tubulin acetylation. We propose that reduced levels of cMyBP-C caused by MYBPC3 mutations trigger HSPs and α-tubulin acetylation, and may present a pathomechanism in cMyBP-C haloinsufficiency-mediated HCM. The possible impact of the observed PQC changes is discussed below.

![Figure 7](image-url)

**Figure 7.** Schematic representation of PQC and microtubular system assessment in HCM. Our analyses show that HSPB1, HSPD1 HSPA2, α-tubulin and acetylated α-tubulin were increased in HCM, especially when a sarcomere mutation is present, while HSPB5, HSPB7, HSPA1 and degradation markers are not changed in HCM compared to controls. Levels of α-tubulin (orange balls) and acetylated α-tubulin (small yellow balls attached to α-tubulin in the lumen of polymerized microtubules (blue and orange balls)) were more increased when haploinsufficiency (HI), characterized by lower levels of cardiac myosin-binding protein-C (green lines), was the underlying pathomechanism instead of poison polypeptides (PP). =: similar to controls; ↑: significantly increased compared to controls; ↑↑: highly significantly increased compared to controls; ↓: significantly decreased compared to controls.

### 4.1. Elevated Levels of HSPs in Human HCM

We identified higher levels of HSPB1, HSPD1, and HSPA2 in HCM_{SMN}P compared to controls, which could not be explained by differences in sex and age at operation (Table 5). Our findings are in line with studies in human end-stage heart failure studies samples, which showed increases in HSPD1 and HSPB1 compared to controls [68].

**Cells 2019, 8, x FOR PEER REVIEW** 18 of 27

Overall, our analyses indicate that carrying a HCM-causing mutation affects PQC and α-tubulin acetylation. We propose that reduced levels of cMyBP-C caused by MYBPC3 mutations trigger HSPs and α-tubulin acetylation, and may present a pathomechanism in cMyBP-C haloinsufficiency-mediated HCM. The possible impact of the observed PQC changes is discussed below.

![Figure 7](image-url)

**Figure 7.** Schematic representation of PQC and microtubular system assessment in HCM. Our analyses show that HSPB1, HSPD1 HSPA2, α-tubulin and acetylated α-tubulin were increased in HCM, especially when a sarcomere mutation is present, while HSPB5, HSPB7, HSPA1 and degradation markers are not changed in HCM compared to controls. Levels of α-tubulin (orange balls) and acetylated α-tubulin (small yellow balls attached to α-tubulin in the lumen of polymerized microtubules (blue and orange balls)) were more increased when haploinsufficiency (HI), characterized by lower levels of cardiac myosin-binding protein-C (green lines), was the underlying pathomechanism instead of poison polypeptides (PP). =: similar to controls; ↑: significantly increased compared to controls; ↑↑: highly significantly increased compared to controls; ↓: significantly decreased compared to controls.

### 4.1. Elevated Levels of HSPs in Human HCM

We identified higher levels of HSPB1, HSPD1, and HSPA2 in HCM_{SMN}P compared to controls, which could not be explained by differences in sex and age at operation (Table 5). Our findings are in line with studies in human end-stage heart failure studies samples, which showed increases in HSPD1 and HSPB1 compared to controls [68].
HSPB1 is implicated in different cardio-protective processes involving interception of misfolded proteins, cytoskeletal organization, anti-apoptotic and anti-oxidant properties [69]. Therefore, its expression may improve the resistance of tissue exposed to stress and injuries [70]. While moderate cardiac expression of HSPB1 protects against doxorubicin-induced cardiac dysfunction through anti-oxidative stress, reports on the effects of HSPB1 overexpression have been inconsistent [71]. Overexpression of HSPB1 conferred protection against myocardial ischemia-reperfusion injury [72], whereas overexpression of HSPB1 caused reductive stress and cardiomyopathy in another study [73]. Further experiments are needed to clarify if the observed increase in HSPB1 is actually beneficial and may be a response to stress exposure.

HSPD1 fulfills multiple tasks in a cell by refolding key proteins after their import into the mitochondria, transporting proteins between the mitochondrial matrix and the cytoplasm of the cell, and binding to cytosolic pro-apoptotic proteins to sequester them [74]. Upregulation of HSPD1 due to mitochondrial impairment is suggested to be an indicator of mitochondrial stress [75]. A total of 15–20% of HSPD1 is located at extra-mitochondrial sites, suggesting important physiological roles at other locations [61]. In human end-stage heart failure, HSPD1 localizes to the plasma membrane, thereby losing anti-apoptotic and protective effects and becoming detrimental to the cell [76]. Impairment of HSPD1-mediated anti-stress response has been reported in dilated cardiomyopathy (DCM) which progressed to end stage heart failure [77]. Here, we identified higher levels of HSPD1, which may indicate mitochondrial stress, as has been reported in HCM [78].

The Western blot analysis showed higher levels of HSPA2 in HCM_SMP compared to controls. In our mass-spectrometry-based proteomics study, HSPA2 was highly upregulated in cardiac disease (Figure 8A) [64]. HSPA2 has been reported in heart tissue and low expression was identified in fibroblasts [60,79]. Recently, HSPA-family chaperones have been suggested to interact with cMyBP-C to regulate its turnover [80]. Moreover, a significant inverse linear correlation was present between cMyBP-C protein levels and HSPA2 (Figure 8B). Therefore, HSPA2 may be an additional regulator of cMyBP-C. Further experiments are warranted to explain the role of HSPA2 in haploinsufficiency for cMyBP-C.

In contrast, the levels of the HSPB5 and HSPA1 in HCM samples were not different compared to controls after adjusting for sex and age differences. Several studies have shown that HSPB5 and HSPA1 are both increased early in response to acute hypertrophic signaling, but with opposite functions. While HSPB5 is involved in counteracting acute cardiac remodeling by suppressing hypertrophic signaling pathways, HSPA1 supports pro-hypertrophic signaling pathways [81,82]. The increase of HSPA1 was transient and attenuated 14 days after isoproterenol-infusion in a mouse model for cardiac hypertrophy [82]. Consistent with our findings in myectomy samples from patient with advanced disease, HSPA1 levels were not changed in septal myectomy samples of HCM patients and end-stage heart failure patients compared to controls [68,80]. Increased HSPA1 in the heart protects against acute cardiac stress, but not against chronic cardiac stress [83].

Based on these studies, we propose that HSPB5 and HSPA1 levels were not changed in the HCM myectomy samples because of persistent chronic hypertrophic stimuli leading to their blunted response. Further research is warranted to investigate if the failure to increase HSPB5 implies a loss of responsiveness at advanced disease stage because HSPB5 seems to play a beneficial role in hypertrophic signaling.
A wide range of cardiac pathologies [62,88]. Pre-clinical models of pressure overload-induced cardiac α-tubulin acetylation and the levels of all HSPs. Changes of microtubules distribution occurred at the onset of hypertrophy [90]. In chronically hypertrophied hearts, the increase of microtubules has been shown to be a major cause of contractile defects [91]. Two different hypotheses may explain microtubule densification:

Figure 6A, which correlated with an increase in α-tubulin acetylation and the levels of all HSPs. Changes of microtubules distribution occurred at the onset of hypertrophy [90]. In chronically hypertrophied hearts, the increase of microtubules has been shown to be a major cause of contractile defects [91]. Two different hypotheses may explain microtubule densification:

4.2. Protein Degradation in HCM

Defects in the turnover of key sarcomere proteins may account for both hypertrophic and functional defects [9]. UPS dysfunction is characterized by the accumulation of ubiquitinated proteins, altered proteasome activity, and changes in expression of UPS proteins or E2 and E3 enzymes [84]. Upon correction for sex and age, no significant changes were observed in the levels of degradation-associated markers in HCM, such as HSPB7, ubiquitin, p62 and LC3BII. Compared to the protein folding-supportive HSPB1 and HSPB5, HSPB7 plays a critical role in preventing protein aggregation [85]. Genetic variants in HSPB7 have been associated with advanced heart failure and systolic dysfunction [86]. In a zebrafish model, HSPB7 was involved in early post-damage processing of large cytoskeletal proteins and the loss of HSPB7 function was accompanied by an increased damaged protein load, protein aggregation and a risk of cardiomyopathy [87]. Due to the use of an antibody recognizing both K48- and K63-linked polyubiquitinated chains, we do not know if the ratio between K48- and K63-linked polyubiquitinated proteins was altered in HCM. Therefore, we cannot draw any conclusion about the functionality of the proteasome, which would be indicated by an increase in K48-linked polyubiquitinated proteins. LC3BII and p62 are both markers for autophagosomes because in selective autophagy, the cargo adapter protein p62 links polyubiquitinated proteins to the autophagic machinery via LC3 [88]. We did not find a change in autophagosome markers, but this finding does not exclude the prospect that the autophagic flux might be impaired. Autophagy has been implicated in the pathogenesis of a wide range of cardiac pathologies [62,88]. Pre-clinical models of pressure overload-induced cardiac hypertrophy showed that the increase of autophagic flux correlated with the degree of hypertrophy and therapeutic inhibition of autophagy was accompanied by reduced amount of fibrosis [89].

Our analysis of protein degradation markers indicates that there is no enhancement of protein degradation pathways at the time of myectomy. This may indicate that boosting protein degradation may actually represent a treatment option to prevent cardiac dysfunction and remodeling.

4.3. Increased Mutation-Dependent Proliferation and Acetylation of α-tubulin

Our protein analyses revealed significantly increased levels of α-tubulin in both HCM groups (Figure 6A), which correlated with an increase in α-tubulin acetylation and the levels of all HSPs. Changes of microtubules distribution occurred at the onset of hypertrophy [90]. In chronically hypertrophied hearts, the increase of microtubules has been shown to be a major cause of contractile defects [91]. Two different hypotheses may explain microtubule densification:
Cells 2019, 8, 741

(1) microtubules may be involved in myofibrillogenesis and an increase in microtubules would be required when new myofibrils are formed in hypertrophied cardiomyocytes, and (2) microtubules may be intracellular compression-bearing elements needed to cope with increased contractile stress on cardiomyocytes [92,93]. In failing human hearts, the accumulation of microtubules impedes sarcomere motion and contributes to a decreased ventricular compliance [94]. Our results are in line with literature, showing an increase in α-tubulin in the HCM myocardial tissue [95]. The underlying pathomechanism seems to have an effect on extent of increase in α-tubulin and acetylated α-tubulin, since we observed the largest increase in samples with haploinsufficiency for cMyBP-C.

An intact microtubule-based cytoskeleton contributes to the stabilization of myofibril structure in the cardiomyocytes and HSPs may preserve this relationship [96]. Post-chaperonin tubulin-folding cofactors, such as HSPs and other tubulin-associated proteins, regulate the synthesis, transport, and storage of α- and β-tubulin [97]. For instance, HSPA1 binds to native tubulin dimers and microtubules to assist in proper tubulin folding [98]. In addition, HSPB5 prevents the aggregation of tubulin and the chaperone activity is accompanied by the formation of large complexes between HSPB5 and tubulin [99]. We identified that α-tubulin level significantly correlates with all the investigated HSPs.

In addition to HSPs, acetylation of α-tubulin was higher in both HCM groups (Figure 6B). Acetylation of α-tubulin directly tunes the compliance and resilience from mechanical breakage to ensure the persistence of long-lived microtubules [100]. Moreover, acetylation of α-tubulin most often compartmentalizes on the stable microtubules and is suggested to increase the assembly of autophagic cargo along microtubules, thereby initiating augmented autophagic degradation in the heart [101,102]. Interestingly, there is a strong linear relation between acetylated and total α-tubulin levels (Figure 6D). This may suggest hyperacetylation of α-tubulin, which is a common response to several cellular stresses. For example, acetyltransferase induction is triggered by the release of mitochondrial reactive oxygen species (ROS) and by AMP kinase [103,104]. Noteworthily, the underlying pathomechanism (HI versus PP) seems to have an effect on the extent of the increase in α-tubulin and the acetylation of α-tubulin, since we observed the largest increase in samples with haploinsufficiency for cMyBP-C. As such, our analyses suggest that proliferation of the microtubular network represents a pathomechanism in HI-mediated HCM. Based on previous studies [100–104], we propose that the increased tubulin network may function to maintain cellular stability and enhance autophagic flux of damaged proteins, while it may impair contractile function [95,105]. Future studies are warranted to establish this link (cause-consequence) between reduced cMyBP-C protein levels, increased α-tubulin acetylation and cardiomyocyte contractile function and hypertrophy that may underlie initiation and progression of cardiac disease in MYBPC3 mutation carriers.

4.4. Inter-Individual Differences

We observed large inter-individual differences in various key PQC players and tubulin networks, especially in the presence of a sarcomere mutation. This variability may be explained by the large variability among HCM-causing mutations, which may all have a distinct effect on cellular PQC. Most of the mutation sites of proteins affect stability and aggregation but rarely its function [106]. This concept is supported by the fact that HCM_HI mutations cause a rather heterogeneous cMyBP-C haploinsufficiency, with some samples having relatively low cMyBP-C, and others having still relatively high protein level. The loss of cMyBP-C levels correlates very well with α-tubulin, thereby supporting the diverse response to a change in sarcomere protein composition in the case of HCM_HI. The microtubule response correlates significantly with the expression level of cMyBP-C, and may represent a direct compensation for the loss of cMyBP-C as cMyBP-C is known to have a central regulatory role in myofibril development and stability [107]. In line with this, reduced myofibril density was detected in septal myectomy samples from HCM_SMP patients compared to HCM_SMN patients [18]. While the excessive microtubular response to cMyBP-C haploinsufficiency may be an attempt to maintain myofibril stability, it may aggravate cardiac dysfunction by altering cytoskeletal mechanical properties [95,105].
5. Conclusions

In summary, our data show that the hypertrophied muscle of HCM patients is characterized by an increased and stabilized tubular network which may be an adaptive response to cardiomyocyte growth. While this compensatory response may aid to stabilize cardiomyocyte architecture, this structural adaption may contribute to a reduced function of the HCM myocardium.

Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/7/741/s1.

Author Contributions: L.M.D., D.W.D.K., B.J.M.B and J.v.d.V conceived, designed and coordinated the study and wrote the manuscript. L.D. and M.S. performed and/or analyzed the experiments. C.d.R., A.F.L.S., P.L.d.J. and M.M. provided the heart samples and patient data and gave input for the manuscript. All authors reviewed the manuscript.

Funding: We acknowledge the support from The Netherlands Cardiovascular Research Initiative: An initiative with support of the Dutch Heart Foundation, CVON2014-40 DOSIS and CVON-STW2016-14728 AFFIP.

Acknowledgments: We would like to thank Ruud Zaremba for technical assistance with the LC3BII Western blots and Peter van de Ven for statistical analyses.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Semsarian, C.; Ingles, J.; Maron, M.S.; Maron, B.J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2015, 65, 1249–1254. [CrossRef] [PubMed]
2. Michels, M.; Olivotto, I.; Asselbergs, F.W.; van der Velden, J. Life-long tailoring of management for patients with hypertrophic cardiomyopathy: Awareness and decision-making in changing scenarios. Neth. Heart J. 2017, 25, 186–199. [CrossRef] [PubMed]
3. Van der Velden, J.; Stienen, G.J.M. Cardiac disorders and pathophysiology of sarcomeric proteins. Physiol. Rev. 2019, 99, 381–426. [CrossRef] [PubMed]
4. Maron, B.J.; Olivotto, I.; Spirito, P.; Casey, S.A.; Bellone, P.; Gohman, T.E.; Graham, K.J.; Burton, D.A.; Cecchi, F. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral-based patient population. Circulation 2000, 102, 858–864. [CrossRef] [PubMed]
5. Ho, C.Y.; Day, S.M.; Ashley, E.A.; Michels, M.; Pereira, A.C.; Jacoby, D.; Cirino, A.L.; Fox, J.C.; Lakdawala, N.K.; Ware, J.S.; et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the sarcomeric human cardiomyopathy registry (share). Circulation 2018, 138, 1387–1398. [CrossRef] [PubMed]
6. Willis, M.S.; Patterson, C. Proteotoxicity and cardiac dysfunction–alzheimer’s disease of the heart? N. Engl. J. Med. 2013, 368, 455–464. [CrossRef]
7. Henning, R.H.; Brundel, B. Proteostasis in cardiac health and disease. Nat. Rev. Cardiol. 2017, 14, 637–653. [CrossRef]
8. Wang, X.; Robbins, J. Heart failure and protein quality control. Circ. Res. 2006, 99, 1315–1328. [CrossRef]
9. Wang, X.; Su, H.; Ranek, M.J. Protein quality control and degradation in cardiomyocytes. J. Mol. Cell Cardiol. 2008, 45, 11–27. [CrossRef]
10. Latchman, D.S. Heat shock proteins and cardiac protection. Cardiovasc. Res. 2001, 51, 637–646. [CrossRef]
11. Tannous, P.; Zhu, H.; Nemchenko, A.; Berry, J.M.; Johnstone, J.L.; Shelton, J.M.; Miller, F.I., Jr.; Rothermel, B.A.; Hill, J.A. Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy. Circulation 2008, 117, 3070–3078. [CrossRef] [PubMed]
12. Sontag, E.M.; Vonk, W.I.M.; Frydman, J. Sorting out the trash: The spatial nature of eukaryotic protein quality control. Curr. Opin. Cell Biol. 2014, 26, 139–146. [CrossRef] [PubMed]
13. Marston, S.; Copeland, O.; Jacques, A.; Livesey, K.; Tsang, V.; McKenna, W.J.; Jalilzadeh, S.; Carballo, S.; Redwood, C.; Watkins, H. Evidence from human myectomy samples that mybp3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ. Res. 2009, 105, 219–222. [CrossRef] [PubMed]
14. Seidman, J.G.; Seidman, C. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell 2001, 104, 557–567. [CrossRef]
15. Vriesendorp, P.A.; Schinkel, A.F.; Soliman, O.I.; Kofflard, M.J.; de Jong, P.L.; van Herwerden, L.A.; Ten Cate, F.J.; Michels, M. Long-term benefit of myectomy and anterior mitral leaflet extension in obstructive hypertrophic cardiomyopathy. Am. J. Cardiol. 2015, 115, 670–675. [CrossRef] [PubMed]

16. Van Velzen, H.G.; Vriesendorp, P.A.; Oldenburg, R.A.; van Slegtenhorst, M.A.; van der Velden, J.; Schinkel, A.F.L.; Michels, M. Value of genetic testing for the prediction of long-term outcome in patients with hypertrophic cardiomyopathy. Am. J. Cardiol. 2016, 118, 881–887. [CrossRef] [PubMed]

17. Parbhudaya, R.Y.; Garra, A.R.; Gotte, M.J.W.; Michels, M.; Pei, J.; Harakalova, M.; Asselbergs, F.W.; van Rossum, A.C.; van der Velden, J.; Kuster, D.W.D. Variable cardiac myosin binding protein-c expression in the myofilaments due to mybpc3 mutations in hypertrophic cardiomyopathy. J. Mol. Cell Cardiol. 2018, 123, 59–63. [CrossRef] [PubMed]

18. Witjas-Paalberends, E.R.; Piroddi, N.; Stam, K.; van Dijk, S.J.; Oliviera, V.S.; Ferrara, C.; Scellini, B.; Hazebroek, M.; ten Cate, F.J.; van Slegtenhorst, M.; et al. Mutations in myh7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc. Res. 2013, 99, 432–441. [CrossRef] [PubMed]

19. Witjas-Paalberends, E.R.; Guclu, A.; Germans, T.; Knaapen, P.; Harms, H.J.; Vermeer, A.M.; Christiaans, I.; Wilde, A.A.; Dos Remedios, C.; Lammertasma, A.A.; et al. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc. Res. 2014, 103, 248–257. [CrossRef] [PubMed]

20. Nijenkamp, L.; Bollen, I.A.E.; van Velzen, H.G.; Regan, J.A.; van Slegtenhorst, M.; Niessen, H.W.M.; Schinkel, A.F.L.; Kruger, M.; Poggesi, C.; Ho, C.Y.; et al. Sex differences at the time of myectomy in hypertrophic cardiomyopathy. Circ. Heart Fail. 2018, 11, e004133. [CrossRef] [PubMed]

21. van Dijk, S.J.; Paalberends, E.R.; Najafi, A.; Michels, M.; Sadayappan, S.; Carrier, L.; Boontje, N.M.; Kuster, D.W.; van Slegtenhorst, M.; Dooijes, D.; et al. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. Circ. Heart Fail. 2012, 5, 36–46. [CrossRef] [PubMed]

22. Kuster, D.W.; Mulders, J.; Ten Cate, F.J.; Michels, M.; Dos Remedios, C.G.; da Costa Martins, P.A.; van der Velden, J.; Oudejans, C.B. Microrna transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with mybpc3 mutations. J. Mol. Cell Cardiol. 2013, 65, 59–66. [CrossRef] [PubMed]

23. Sequeira, V.; Najafi, A.; Wijnker, P.J.; Dos Remedios, C.G.; Michels, M.; Kuster, D.W.; van der Velden, J. Adp-stimulated contraction: A predictor of thin-filament activation in cardiac disease. Proc. Natl. Acad. Sci. USA 2015, 112, E7003–E7012. [CrossRef] [PubMed]

24. Van Dijk, S.J.; Boontje, N.M.; Heymans, M.W.; Ten Cate, F.J.; Michels, M.; Dos Remedios, C.; Dooijes, D.; van Slegtenhorst, M.; Stienen, G.J. Preserved cross-bridge kinetics in human hypertrophic cardiomyopathy patients with mybpc3 mutations. Pflug. Arch. 2014, 466, 1619–1633. [CrossRef] [PubMed]

25. Sequeira, V.; Wijnker, P.J.; Nijenkamp, L.L.; Kuster, D.W.; Najafi, A.; Witjas-Paalberends, E.R.; Regan, J.A.; Boontje, N.; Ten Cate, F.J.; Germans, T.; et al. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ. Res. 2013, 112, 1491–1505. [CrossRef] [PubMed]

26. Witjas-Paalberends, E.R.; Ferrara, C.; Scellini, B.; Piroddi, N.; Montag, J.; Tesi, C.; Stienen, G.J.; Michels, M.; Ho, C.Y.; Kraft, T.; et al. Faster cross-bridge detachment and increased tension cost in human hypertrophic cardiomyopathy with the r403q myh7 mutation. J. Physiol. 2014, 592, 3257–3272. [CrossRef]

27. Robinson, A.A.; Dunn, M.J.; McCormack, A.; dos Remedios, C.; Rose, M.L. Protective effect of phosphorylated hsp27 in coronary arteries through actin stabilization. J. Mol. Cell Cardiol. 2010, 49, 370–379. [CrossRef]

28. Polden, J.; McManus, C.A.; Dos Remedios, C.; Dunn, M.J. A 2-d gel reference map of the basic human heart proteome. Proteomics 2011, 11, 3582–3586. [CrossRef]

29. Narolska, N.A.; Piroddi, N.; Belus, A.; Boontje, N.M.; Scellini, B.; Deppermann, S.; Zaremba, R.; Musters, R.J.; dos Remedios, C.; Jaquet, K.; et al. Impaired diastolic function after exchange of endogenous troponin i with c-terminal truncated troponin i in human cardiac muscle. Circ. Res. 2006, 99, 1012–1020. [CrossRef]

30. Zhang, P.; Kirk, J.A.; Ji, W.; dos Remedios, C.G.; Kass, D.A.; Van Eyk, J.E.; Murphy, A.M. Multiple reaction monitoring to identify site-specific troponin i phosphorylated residues in the failing human heart. Circulation 2012, 126, 1828–1837. [CrossRef]
31. Kooij, V.; Zhang, P.; Piersma, S.R.; Sequeira, V.; Boontje, N.M.; Wijnker, P.J.; Jimenez, C.R.; Jaquet, K.E.; dos Remedios, C.; Murphy, A.M.; et al. Pkcalpha-specific phosphorylation of the troponin complex in human myocardium: A functional and proteomics analysis. *PloS ONE* **2013**, *8*, e74847. [CrossRef] [PubMed]

32. Wijnker, P.J.; Li, Y.; Zhang, P.; Foster, D.B.; dos Remedios, C.; Van Eyk, J.E.; Stienen, G.J.; Murphy, A.M.; van der Velden, J. A novel phosphorylation site, serine 199, in the C-terminus of cardiac troponin I regulates calcium sensitivity and susceptibility to calpain-induced proteolysis. *J. Mol. Cell Cardiol.* **2015**, *82*, 93–103. [CrossRef] [PubMed]

33. Krysiak, J.; Unger, A.; Beckendorf, L.; Hamdani, N.; von Frieling-Salewsky, M.; Redfield, M.M.; Dos Remedios, C.G.; Sheikh, F.; Gergs, U.; Boknik, P.; et al. Protein phosphatase 5 regulates titin phosphorylation and function at a sarcomere-associated mechanosensor complex in cardiomyocytes. *Nat. Commun.* **2018**, *9*, 262. [CrossRef] [PubMed]

34. Gotzmann, M.; Grabbe, S.; Schone, D.; von Frieling-Salewsky, M.; Dos Remedios, C.G.; Strauch, J.; Bechtel, M.; Dietrich, J.W.; Tannapfel, A.; Mugge, A.; et al. Alterations in titin domain properties and myocardial fibrosis correlate with clinical phenotypes in hemodynamic subgroups of severe aortic stenosis. *Jacc. Basic Transl. Sci.* **2018**, *3*, 335–346. [CrossRef] [PubMed]

35. Kruger, M.; Kotter, S.; Grutzner, A.; Lang, P.; Andresen, C.; Redfield, M.M.; Butt, E.; dos Remedios, C.G.; Linke, W.A. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. *Circ. Res.* **2009**, *104*, 87–94. [CrossRef] [PubMed]

36. Kotter, S.; Gout, L.; Von Frieling-Salewsky, M.; Muller, A.E.; Hellung, S.; Marcus, K.; Dos Remedios, C.; Linke, W.A.; Kruger, M. Differential changes in titin domain phosphorylation increase myofilament stiffness in failing human hearts. *Cardiovasc. Res.* **2013**, *99*, 648–656. [CrossRef] [PubMed]

37. Huang, Z.P.; Ding, Y.; Chen, J.; Wu, G.; Kataoka, M.; Hu, Y.; Yang, J.H.; Liu, J.; Drakos, S.G.; Selzman, C.H.; et al. Long non-coding ras exacel cellular matrix gene expression to ischemic cardiomyopathy. *Cardiovasc. Res.* **2016**, *112*, 543–554. [CrossRef] [PubMed]

38. Lin, Z.; Guo, H.; Cao, Y.; Zohrabian, S.; Zhou, P.; Ma, Q.; VanDusen, N.; Guo, Y.; Zhang, J.; Stevens, S.M.; et al. Acetylation of vgll4 regulates hippo-yap signaling and postnatal cardiac growth. *Dev. Cell* **2016**, *39*, 466–479. [CrossRef] [PubMed]

39. Kong, S.W.; Hu, Y.W.; Ho, J.W.; Ikeda, S.; Polster, S.; John, R.; Hall, J.L.; Bisping, E.; Pieske, B.; dos Remedios, C.G.; et al. Heart failure-associated changes in rna splicing of sarcomere genes. *Circ. Cardiovasc. Genet.* **2010**, *3*, 138–146. [CrossRef] [PubMed]

40. Lu, Z.; Xu, X.; Hu, X.; Lee, S.; Traverse, J.H.; Zhu, G.; Fassett, J.; Tao, Y.; Zhang, P.; dos Remedios, C.; et al. Oxidative stress regulates left ventricular pde5 expression in the failing heart. *Circulation* **2010**, *121*, 1474–1483. [CrossRef] [PubMed]

41. Fermin, D.R.; Barac, A.; Lee, S.; Polster, S.P.; Hannenhalli, S.; Bergemann, T.L.; Grindle, S.; Dyke, D.B.; Pagani, F.; Miller, L.W.; et al. Sex and age dimorphism of myocardial gene expression in nonischemic human heart failure. *Circ. Cardiovasc. Genet.* **2008**, *1*, 117–125. [CrossRef] [PubMed]

42. McNamara, J.W.; Li, A.; Lal, S.; Bos, J.M.; Harris, S.P.; van der Velden, J.; Ackerman, M.J.; Cooke, R.; Dos Remedios, C.G. Mybpc3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy. *PloS ONE* **2017**, *12*, e0180064. [CrossRef] [PubMed]

43. Montag, J.; Syring, M.; Rose, J.; Weber, A.L.; Ernstberger, P.; Mayer, A.K.; Becker, E.; Keyser, B.; Dos Remedios, C.; Perrot, A.; et al. Intrinsic myh7 expression regulation contributes to tissue level allelic imbalance in hypertrophic cardiomyopathy. *J. Muscle Res. Cell Motil.* **2017**, *38*, 291–302. [CrossRef] [PubMed]

44. Montag, J.; Kowalski, K.; Makul, M.; Ernstberger, P.; Radocaj, A.; Beck, J.; Becker, E.; Tripathi, S.; Keyser, B.; Muhlfeld, C.; et al. Burst-like transcription of mutant and wildtype myh7-alleles as possible origin of cell-to-cell contractile imbalance in hypertrophic cardiomyopathy. *Front. Physiol.* **2018**, *9*, 359. [CrossRef] [PubMed]

45. Iorga, B.; Schwanke, K.; Weber, N.; Wendland, M.; Greten, S.; Piep, B.; Dos Remedios, C.G.; Martin, U.; Zweierdt, R.; Kraft, T.; et al. Differences in contractile function of myofibrils within human embryonic stem cell-derived cardiomyocytes vs. Adult ventricular myofibrils are related to distinct sarcomeric protein isoforms. *Front. Physiol.* **2017**, *8*, 1111. [CrossRef]

46. Messer, A.E.; Gallon, C.E.; McKenna, W.J.; Dos Remedios, C.G.; Marston, S.B. The use of phosphate-affinity sds-page to measure the cardiac troponin i phosphorylation site distribution in human heart muscle. *Proteom. Clin. Appl.* **2009**, *3*, 1371–1382. [CrossRef] [PubMed]
47. Hoskins, A.C.; Jacques, A.; Bardswell, S.C.; McKenna, W.J.; Tsang, V.; dos Remedios, C.G.; Ehler, E.; Adams, K.; Jalilzadeh, S.; Avkiran, M.; et al. Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy. J. Mol. Cell Cardiol. 2010, 49, 737–745. [CrossRef] [PubMed]

48. Bayliss, C.R.; Jacques, A.M.; Leung, M.C.; Ward, D.G.; Redwood, C.S.; Gallon, C.E.; Copeland, O.; McKenna, W.J.; dos Remedios, C.; Marston, S.B.; et al. Myofibrillar ca(2+)-sensitivity is uncoupled from troponin i phosphorylation in hypertrophic obstructive cardiomyopathy due to abnormal troponin t. Cardiovasc. Res. 2013, 97, 500–508. [CrossRef] [PubMed]

49. Messer, A.E.; Bayliss, C.R.; El-Mezgueldi, M.; Redwood, C.S.; Ward, D.G.; Leung, M.C.; Papadaki, M.; dos Remedios, C.; Marston, S.B. Mutations in troponin t associated with hypertrophic cardiomyopathy increase ca(2+)-sensitivity and suppress the modulation of ca(2+)-sensitivity by troponin i phosphorylation. Arch. Biochem. Biophys. 2016, 601, 113–120. [CrossRef] [PubMed]

50. Mamidi, R.; Gresham, K.S.; Li, A.; dos Remedios, C.G.; Stelzer, J.E. Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-c. J. Mol. Cell Cardiol. 2015, 85, 262–272. [CrossRef]

51. Mamidi, R.; Li, J.; Gresham, K.S.; Verma, S.; Doh, C.Y.; Li, A.; Lal, S.; dos Remedios, C.G.; Stelzer, J.E. Dose-dependent effects of the myosin activator omecamtiv mecarbil on cross-bridge behavior and force generation in failing human myocardium. Circ. Heart Fail. 2017, 10. [CrossRef] [PubMed]

52. Coats, C.J.; Heywood, W.E.; Virasami, A.; Ashrafi, N.; Syrris, P.; dos Remedios, C.; Treibel, T.A.; Moon, J.C.; Lopes, L.R.; McGregor, C.G.A.; et al. Proteomic analysis of the myocardium in hypertrophic obstructive cardiomyopathy. Circ. Genom. Precis. Med. 2018, 11, e001974. [CrossRef] [PubMed]

53. Mollova, M.; Bersell, K.; Walsh, S.; Savla, J.; Das, L.T.; Park, S.Y.; Silberstein, L.E.; dos Remedios, C.G.; Ayaz-Guner, S.; Cai, W.; Martin-Garrido, A.; Biesiadecki, B.J.; Salhi, H.E.; Shaifta, Y.; dos Remedios, C.G.; Drake, J.I.; Gomez-Arroyo, J.; Mizuno, S.; Szczepanek, K.; Van Tassell, B.; Natarajan, R.; dos Remedios, C.G.; Bordeaux, J.; Ahmadi, Y.; Bollen, I.A.E.; Ehler, E.; Fleischanderl, K.; Bouwman, F.; Colan, S.; et al. Myofilament remodeling and function is more impaired in peripartum cardiomyopathy compared with dilated cardiomyopathy and ischemic heart disease. Proc. Natl. Acad. Sci. USA 2013, 110, 1446–1451. [CrossRef] [PubMed]

54. Polizzotti, B.D.; Ganapathy, B.; Walsh, S.; Choudhury, S.; Ammanamanchi, N.; Bennett, D.G.; dos Remedios, C.G.; Haubner, B.J.; Penninger, J.M.; Kuhn, B. Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window. Sci. Transl. Med. 2015, 7, 281ra245. [CrossRef] [PubMed]

55. Bollen, I.A.E.; Ehler, E.; Fleischanderl, K.; Bouwman, F.; Kempers, L.; Ricke-Hoch, M.; Hilfiker-Kleiner, D.; Salehpour, M.; Alkass, K.; Bernard, S.; Szewczykowska, M.; Bergmann, O.; Zdunek, S.; Felker, A.; Salehpour, M.; Alkass, K.; Bernard, S.; Szewczykowska, M.; Jackowska, T.; dos Remedios, C.; et al. Dynamics of cell generation and turnover in the human heart. Cell 2015, 161, 1566–1575. [CrossRef] [PubMed]

56. Bergmann, O.; Zdunek, S.; Felker, A.; Salehpour, M.; Alkass, K.; Bernard, S.; Sjostrom, S.L.; Szewczykowska, M.; Jackowska, T.; dos Remedios, C.; et al. Cardiomyocyte proliferation contributes to heart growth in young humans. Proc. Natl. Acad. Sci. USA 2013, 110, 1446–1451. [CrossRef] [PubMed]

57. Gomez-Arroyo, J.; Mizuno, S.; Szczepanek, K.; Van Tassell, B.; Natarajan, R.; dos Remedios, C.G.; Drake, J.I.; Farkas, L.; Kraska, K.; Wijesinghe, D.S.; et al. Myofilament remodeling and function is more impaired in peripartum cardiomyopathy compared with dilated cardiomyopathy and ischemic heart disease. Am. J. Pathol. 2017, 187, 2645–2658. [CrossRef] [PubMed]

58. Dorsch, L.M.; Schuldt, M.; Knezevic, D.; Wiersma, M.; Kuster, D.W.D.; van der Velden, J.; Brandt, B. Untying the knot: Protein quality control in inherited cardiomyopathies. Pflug. Arch. 2018, 470, 785–798. [CrossRef]

59. Piroddi, N.; Witjas-Paalberends, E.R.; Ferrara, C.; Ferrantini, C.; Vitale, G.; Scellini, B.; Wijnker, P.J.M.; Sequiera, V.; Dooijes, D.; dos Remedios, C.; et al. The homozygous k280n troponin t mutation alters cross-bridge kinetics and energetics in human hcm. J. Gen. Physiol. 2019, 151, 18–29. [CrossRef] [PubMed]

60. Brocchieri, L.; Conway de Macario, E.; Macario, A.J. Hsp70 genes in the human genome: Conservation and differentiation patterns predict a wide array of overlapping and specialized functions. Bmc. Evol. Biol. 2008, 8, 19. [CrossRef] [PubMed]
63. van Dijk, S.J.; Dooijes, D.; dos Remedios, C.; Michels, M.; Lamers, J.M.; Winegrad, S.; Schlossarek, S.; Carrier, L.; ten Cate, F.J.; Stienen, G.J.; et al. Cardiac myosin-binding protein c mutations and hypertrophic cardiomyopathy: Haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. *Circulation* **2009**, *119*, 1473–1483. [CrossRef]

64. Schuldt, M.; Pei, J.; Harakalova, M.; Dorsch, L.M.; Mokry, M.; Knol, J.C.; Pham, T.V.; Schelfhorst, T.; Piersma, S.R.; dos Remedios, C.; et al. Detyrosinated tubulin as treatment target in genetic heart disease: Proteomic and functional studies in hypertrophic cardiomyopathy. Status: Manuscript in preparation.

65. Matsuyama, A.; Shimazu, T.; Sumida, Y.; Saito, A.; Yoshimatsu, Y.; Seigneurin-Berny, D.; Osada, H.; Komatsu, Y.; Nishino, N.; Knochbin, S.; et al. In vivo destabilization of dynamic microtubules by hdac6-mediated deacetylation. *Embo J.* **2002**, *21*, 6820–6831. [CrossRef]

66. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.F.; Yao, T.P. Hdac6 is a microtubule-associated deacetylase. *Nature* **2002**, *417*, 455–458. [CrossRef]

67. Ng, D.C.; Ng, I.H.; Yeap, Y.Y.; Badrian, B.; Tsoutsman, T.; McMullen, J.R.; Sensarion, C.; Bogoyevitch, M.A. Opposing actions of extracellular signal-regulated kinase (erk) and signal transducer and activator of transcription 3 (stat3) in regulating microtubule stabilization during cardiac hypertrophy. *J. Biol. Chem.* **2011**, *286*, 1576–1587. [CrossRef]

68. Knowlton, A.A.; Kapadia, S.; Torre-Amione, G.; Durand, J.B.; Bies, R.; Young, J.; Mann, D.L. Differential expression of heat shock proteins in normal and failing human hearts. *J. Mol. Cell Cardiol.* **1998**, *30*, 811–818. [CrossRef]

69. Benjamin, I.J.; McMillan, D.R. Stress (heat shock) proteins: Molecular chaperones in cardiovascular biology and disease. *Circ. Res.* **1998**, *83*, 117–132. [CrossRef]

70. Arrigo, A.P. Mammalian hspb1 (hsp27) is a molecular sensor linked to the physiology and environment of the cell. *Cell Stress Chaperones* **2017**, *22*, 517–529. [CrossRef]

71. Liu, L.; Zhang, X.; Qian, B.; Min, X.; Gao, X.; Li, C.; Cheng, Y.; Huang, J. Over-expression of heat shock protein 27 attenuates doxorubicin-induced cardiac dysfunction in mice. *Eur. J. Heart Fail.* **2007**, *9*, 762–769. [CrossRef]

72. Efthymiou, C.A.; Mocanu, M.M.; de Belleroche, J.; Wells, D.J.; Latchmann, D.S.; Yellon, D.M. Heat shock protein 27 protects the heart against myocardial infarction. *Basic Res. Cardiol.* **2004**, *99*, 392–394. [CrossRef]

73. Zhang, X.; Min, X.; Li, C.; Benjamin, I.J.; Qian, B.; Zhang, X.; Ding, Z.; Gao, X.; Yao, J.; Ma, Y.; et al. Involvement of reductive stress in the cardiomyopathy in transgenic mice with cardiac-specific overexpression of heat shock protein 27. *Hypertension* **2010**, *55*, 1412–1417. [CrossRef]

74. Knowlton, A.A.; Srivatsa, U. Heat-shock protein 60 and cardiovascular disease: A paradoxical role. *Future Cardiol.* **2008**, *4*, 151–161. [CrossRef]

75. Pellegrino, M.W.; Nargund, A.M.; Haynes, C.M. Signaling the mitochondrial unfolded protein response. *Biochim. Biophys. Acta* **2013**, *1833*, 410–416. [CrossRef]

76. Lin, L.; Kim, S.C.; Wang, Y.; Gupta, S.; Davis, B.; Simon, S.I.; Torre-Amione, G.; Knowlton, A.A. Hsp60 in heart failure: Abnormal distribution and role in cardiac myocyte apoptosis. *Am. J. Physiol. Heart Circ. Physiol.* **2007**, *293*, H2238–H2247. [CrossRef]

77. Sidorik, L.; Kyyamova, R.; Bobyk, V.; Kapustian, L.; Rozhko, O.; Vigontina, O.; Ryabenko, D.; Danko, I.; Maksymchuk, O.; Kovalenko, V.; et al. Molecular chaperone, hsp60, and cytochrome p450 2e1 co-expression and disease. *Circ. Res.* **2011**, *109*, 117–132. [CrossRef]

78. Unno, K.; Isobe, S.; Izawa, H.; Cheng, X.W.; Basrur, V.; Nesvizhskii, A.I.; Lee, L.M.; Shao, H.; Tang, V.; Yoshida, M.; et al. Hsc70 is a chaperone for wild-type and mutant cardiac myosin binding protein c. *JCI Insight* **2018**, *3*. [CrossRef]

79. Kumarapeli, A.R.; Su, H.; Huang, W.; Tang, M.; Zheng, H.; Horak, K.M.; Li, M.; Wang, X. Alpha b-crystallin suppresses pressure overload cardiac hypertrophy. *Circ. Res.* **2008**, *103*, 1473–1482. [CrossRef]
82. Kee, H.J.; Eom, G.H.; Joung, H.; Shin, S.; Kim, J.R.; Cho, Y.K.; Choe, N.; Sim, B.W.; Jo, D.; Jeong, M.H.; et al. Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy. *Circ. Res.* 2008, 103, 1259–1269. [CrossRef]

83. Bernardo, B.C.; Weeks, K.L.; Patterson, N.L.; McMullen, J.R. Hsp70: Therapeutic potential in acute and chronic cardiac disease settings. *Future Med. Chem.* 2016, 8, 2177–2183. [CrossRef]

84. Day, S.M. The ubiquitin proteasome system in human cardiomyopathies and heart failure. *Am. J. Physiol. Heart Circ. Physiol.* 2013, 304, H1283–H1293. [CrossRef]

85. Vos, M.J.; Zijlstra, M.P.; Kanon, B.; van Waarde-Verhagen, M.A.; Brunt, E.R.; Oosterveld-Hut, H.M.; Carra, S.; Sibon, O.C.; Kampina, H.H. Hspb7 is the most potent polyQ aggregation suppressor within the hspb family of molecular chaperones. *Hum. Mol. Genet.* 2010, 19, 4677–4693. [CrossRef]

86. Villard, E.; Perret, C.; Gary, F.; Proust, C.; Dilanian, G.; Hengstenberg, C.; Ruppert, V.; Arbusini, E.; Wichter, T.; Germain, M.; et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. *Eur. Heart J.* 2011, 32, 1065–1076. [CrossRef]

87. Mercer, E.J.; Lin, Y.F.; Cohen-Gould, L.; Evans, T. Hspb7 is a cardioprotective chaperone facilitating sarcomeric proteostasis. *Dev. Biol.* 2018, 435, 41–55. [CrossRef]

88. Lavandero, S.; Troncoso, R.; Rothermel, B.A.; Martinet, W.; Sadoshima, J.; Hill, J.A. Cardiovascular autophagy: Concepts, controversies, and perspectives. *Autophagy* 2013, 9, 1455–1466. [CrossRef]

89. Weng, L.Q.; Zhang, W.B.; Ye, Y.; Yin, P.P.; Yuan, J.; Wang, X.X.; Kang, L.; Jiang, S.S.; You, J.Y.; Wu, J.; et al. Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in mice. *Acta Pharm. Sin.* 2014, 35, 1005–1014. [CrossRef]

90. Samuel, J.L.; Bertier, B.; Bugaisky, L.; Marotte, F.; Swyngedauw, B.; Schwartz, K.; Rappaport, L. Different distributions of microtubules, desmin filaments and isomyosins during the onset of cardiac hypertrophy in the rat. *Eur. J. Cell Biol.* 1984, 34, 300–306.

91. Tagawa, H.; Rozich, J.D.; Tsutsui, H.; Narishige, T.; Kuppuswamy, D.; Sato, H.; McDermott, P.J.; Koide, M.; Cooper, G.t. Basis for increased microtubules in pressure-hypertrophied cardiocytes. *Circulation* 1996, 93, 1230–1243. [CrossRef]

92. Stamenovic, D.; Mijailovich, S.M.; Tolic-Norrelykke, I.M.; Chen, J.; Wang, N. Cell prestress. II. Contribution of microtubules. *Am. J. Physiol. Cell Physiol.* 2002, 282, C617–C624. [CrossRef]

93. Watkins, S.C.; Samuel, J.L.; Marotte, F.; Bertier-Savalle, B.; Rappaport, L. Microtubules and desmin filaments during onset of heart hypertrophy in rat: A double immunoelectron microscope study. *Circ. Res.* 1987, 60, 327–336. [CrossRef]

94. Heling, A.; Zimmermann, R.; Kostin, S.; Maeno, Y.; Hein, S.; Devaux, B.; Bauer, E.; Klovekorn, W.P.; Schlepper, M.; Schaper, W.; et al. Increased expression of cytoskeletal linkage, and extracellular proteins in failing human myocardium. *Circ. Res.* 2000, 86, 846–853. [CrossRef]

95. Robison, P.; Caporizzo, M.A.; Ahmadzadeh, H.; Bogush, A.I.; Chen, C.Y.; Margulies, K.B.; Shenoy, V.B.; Prosser, B.L. Detyrosinated microtubules buckle and bear load in contracting cardiomyocytes. *Science* 2016, 352, aaf659. [CrossRef]

96. Decker, R.S.; Decker, M.L.; Nakamura, S.; Zhao, Y.S.; Hedjbeli, S.; Harris, K.R.; Klocke, F.F. Hsc73-tubulin complex formation during low-flow ischemia in the canine myocardium. *Am. J. Physiol. Heart Circ. Physiol.* 2002, 283, H1322–H1333. [CrossRef]

97. Lopez-Fanarrega, M.; Avila, J.; Guasch, A.; Coll, M.; Zabala, J.C. Review: Postchaperonin tubulin folding cofactors and their role in microtubule dynamics. *J. Struct. Biol.* 2001, 135, 219–229. [CrossRef]

98. Sanchez, C.; Padilla, R.; Paciucci, R.; Zabala, J.C.; Avila, J. Binding of heat-shock protein 70 (hsp70) to tubulin. *Arch Biochem. Biophys.* 1994, 310, 428–432. [CrossRef]

99. Ohto-Fujita, E.; Fujita, Y.; Atomi, Y. Analysis of the alphab-crystallin domain responsible for inhibiting tubulin aggregation. *Cell Stress Chaperones* 2007, 12, 163–171. [CrossRef]

100. Xu, Z.; Schaedel, L.; Portran, D.; Aguilar, A.; Gaillard, J.; Marinkovich, M.P.; They, M.; Nachury, M.V. Microtubules acquire resistance from mechanical breakage through intralumenal acetylation. *Science* 2017, 356, 328–332. [CrossRef]

101. Geeraert, C.; Ratier, A.; Pfisterer, S.G.; Perdiz, D.; Cantaloube, I.; Rouault, A.; Pattingre, S.; Proikas-Cezanne, T.; Codogno, P.; Pous, C. Starvation-induced hyperacetylation of tubulin is required for the stimulation of autophagy by nutrient deprivation. *J. Biol. Chem.* 2010, 285, 24184–24194. [CrossRef]
102. McLendon, P.M.; Ferguson, B.S.; Osinska, H.; Bhuiyan, M.S.; James, J.; McKinsey, T.A.; Robbins, J. Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, E5178–E5186. [CrossRef] [PubMed]

103. Mackeh, R.; Lorin, S.; Ratier, A.; Mejdoubi-Charef, N.; Baille, A.; Bruneel, A.; Hamai, A.; Codogno, P.; Pous, C.; Perdiz, D. Reactive oxygen species, amp-activated protein kinase, and the transcription cofactor p300 regulate alpha-tubulin acetyltransferase-1 (alphatat-1/mec-17)-dependent microtubule hyperacetylation during cell stress. *J. Biol. Chem.* **2014**, *289*, 11816–11828. [CrossRef] [PubMed]

104. Li, L.; Yang, X.J. Tubulin acetylation: Responsible enzymes, biological functions and human diseases. *Cell Mol. Life Sci.* **2015**, *72*, 4237–4255. [CrossRef] [PubMed]

105. Caporizzo, M.A.; Chen, C.Y.; Salomon, A.K.; Margulies, K.B.; Prosser, B.L. Microtubules provide a viscoelastic resistance to myocyte motion. *Biophys. J.* **2018**, *115*, 1796–1807. [CrossRef]

106. DePristo, M.A.; Weinreich, D.M.; Hartl, D.L. Missense meanderings in sequence space: A biophysical view of protein evolution. *Nat. Rev. Genet.* **2005**, *6*, 678–687. [CrossRef] [PubMed]

107. Ehler, E.; Gautel, M. The sarcomere and sarcomerogenesis. *Adv. Exp. Med. Biol.* **2008**, *642*, 1–14.